Intelligence Platform
Patents
Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12350313
Activin receptor type IIa variants and methods of use thereof
granted patentUS 12350399
Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and method
granted patentUS 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hyd
granted patentUS 12351574
Selective ligands for modulation of GIRK channels
granted patentUS 12351614
CLEC9A-based chimeric protein complexes
granted patentUS 12350270
Antimalarial agents
granted patentUS 12350120
Gum-protecting and teeth-whitening strip and preparation method thereof
granted patentUS 12350510
Magnetic microwires for energy-transporting biomedical applications
granted patentUS 12350242
Binge behavior regulators
granted patentUS 12350250
Aggrelytes for treating ocular conditions
granted patentUS 12350245
Stable oral suspensions of baclofen
granted patentUS 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted patentUS 12351850
Methods of producing full-length antibodies using E. coli
granted patentUS 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted patentUS 12351877
Systems and methods for determining a treatment course of action
granted patentUS 12351834
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
granted patentUS 12351824
Method for producing natural killer cells from pluripotent stem cells
granted patentUS 12351653
Pharmaceutical compositions comprising novel cyclic peptides
granted patentUS 12351644
Anti-CD73 antibodies
granted patentUS 12350258
Compositions and methods for treatment of skin-related diseases and promoting dermatologic
granted patentUS 12351625
Therapeutic antibodies against osteopontin
granted patentUS 12351633
PD-1 and PD-L1 binding agents
granted patentUS 12351638
Chimeric antigen receptors targeting BCMA and methods of use thereof
granted patentUS 12351560
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
granted